Author:
Andreoni Massimo,Coppola Nicola,Craxì Antonio,Fagiuoli Stefano,Gardini Ivan,Mangia Alessandra,Nava Felice Alfonso,Pasqualetti Patrizio
Abstract
Abstract
Background
It has been estimated that the incidence of chronic hepatitis C virus (HCV) will not decline over the next 10 years despite the improved efficacy of antiviral therapy because most patients remain undiagnosed and/or untreated. This study aimed to investigate the opinion of relevant target populations on the practicability, effectiveness and best modalities of the test-and-treat approach in the fight against HCV in Italy.
Methods
A survey was delivered to patients with HCV from the general population, patients from drug addiction services, hospital physicians and healthcare providers for drug addiction services.
Results
For both hospital clinicians and SerD HCPs, tolerability is shown as the most important feature of a suitable treatment. Time to treatment (the time from first contact to initiation of treatment) is deemed important to the success of the strategy by all actors. While a tolerable treatment was the main characteristic in a preferred care pathway for general patients, subjects from drug addiction services indicated that a complete Meet–Test–Treat pathway is delivered within the habitual care center as a main preference. This is also important for SerD HCPs who are a strong reference for their patients; hospital clinicians were less aware of the importance of the patient-HCP relationship in this process.
Conclusion
The health system is bound to implement suitable pathways to facilitate HCV eradication. A Meet–Test–Treat program within the drug addiction services may provide good compliance from subjects mainly concerned with virus transmission.
Publisher
Springer Science and Business Media LLC
Reference26 articles.
1. Polaris Observatory. https://cdafound.org/polaris/.
2. Gardini I, Bartoli M, Conforti M, Mennini FS, Marcellusi A, Lanati E. HCV—estimation of the number of diagnosed patients eligible to the new anti-HCV therapies in Italy. Eur Rev Med Pharmacol Sci. 2016;20(1 Suppl):7–10.
3. Mariano A, Scalia Tomba G, Tosti ME, Spada E, Mele A. Estimating the incidence, prevalence and clinical burden of hepatitis C over time in Italy. Scand J Infect Dis. 2009;41:689–99.
4. Scott N, Doyle JS, Wilson DP, et al. Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade. Int J Drug Policy. 2017;47:107–16.
5. Grebely J, Dore GJ, Morin S, et al. Elimination of HCV as a public health concern among people who inject drugs by 2030—what will it take to get there? J Int AIDS Soc. 2017;20:22146.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献